Basic Info.
Mazdutide is a dual agonist of the GLP-1receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM).
The drug is developed by Eli Lilly and is currently in multiple Phase III studies.
In May 2025, a result of Phase III study has shown that once-weekly mazdutide led to clinically relevant reductions in body weight in Chinese adults with overweight or obesity.
Our factory
“Strength builds the foundation, and excellent services reach all over the world.” Create win-win situation with customers
Leave A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.